Navigation Links
Sangui BioTech Files Three 2007 Quarterly Reports, Sales Increased, Losses Continue
Date:6/20/2008

WITTEN, Germany, June 20 /PRNewswire-FirstCall/ -- Sangui BioTech International, Inc., has now filed its quarterly reports on Form 10QSB with the SEC covering the quarters ended September 30, 2006; December 31, 2006, and March 31, 2007. In the first nine month of its 2007 financial year the company generated sales of approximately USD 345,000 as compared to approximately USD 95,000 in the first nine months of FY 2006. Operating expenses amounted to almost USD 600,000. The increase as compared to the USD 356,000 in the previous year period is due to increased efforts to expand operations to international markets. The company incurred a net loss of approximately USD 486,000. Sangui used cash in operating acitivities of approximately USD 457,000 (2006 period: approximately USD 242,000). The company's accumulated deficit amounted to USD 22.3 million as of March 31, 2007.

Apart from the contribution margin generated from sales of its cosmetics and wound management products, operations in the first nine months of FY 2007 were financed by investments from several European investors in the amount of approximately USD 543,000. In accordance with US-GAAP the amount is shown as Foreign currency translation adjustments in the profit-and-loss statement and as Effect of exchange rate changes in the cash-flow statement respectively.

In the first nine months of its financial year 2008 (July 1, 2007 through March 31, 2008), Sangui BioTech International, Inc., generated hardly any sales. The company invested in identifying and establishing new sales opportunities in international markets, to wit Mexico and the Arab countries, as well as in the approval process of its Hemospray wound spray in accordance with European, Mexican and US regulations. Ensuing losses were financed by continued investments from several European investors.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. ('/>"/>

SOURCE Sangui BioTech International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Biotech Finishes on a High in August, Burrill Report Says
3. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
4. Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum
5. Biotech delists shares from TSXV, continues OTCBB trading
6. Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007
7. MichBio Announces Formation of Biotechnology Legislative Caucus
8. Oncolytics Biotech Inc. announces approval for UK clinical trial
9. Not just humans benefit from animal biotechnology
10. Biotech adds Central American markets to Sucanon distribution
11. GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
..., Md., Oct. 29 Sequoia Pharmaceuticals,Inc., whic...ics as well as,pharmacokinetic enhancers, announce...s President and Chief Executive Officer. He will a...Chris Mirabelli, Chairman of the Board of,Sequoia ...
...Guantanamo are bringing these issues to the fore, ...s) -- Too few American medical students receive ad...nd a physician,s ethical duties under the Geneva C...nt had received less than one hour of instruction ...
...LIS While colonoscopy has become widely used for ...screening colonoscopies show no cancer or pre-canc... of the journal Gastroenterology, Thomas F. Imperi...that can help determine who is at risk for colorec...
...es Health Industry Exclusive, ,An Audience With Ja... Contemporary Resort, Orlando, FL, LONDON, Octobe...speak at the 8th Annual Lean Six Sigma Healthcare ...Sigma and process,excellence. http://www.iqpc.co...
...nd Memorial Hermann Reduce Employer Healthcare Cos...able Healthcare, HOUSTON, Oct. 29 As employer he...ate of inflation, there is good news on the,horizo... be particularly effective in improving employee h...
...ia is in crisis in the developing world because of...d equipment, according to His Royal Highness The D...tists of Great Britain and Ireland. , In the for...contrast to the UK where patients undergoing surge...
Other Medicine News:Health News:Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer 2Health News:U.S. Docs Taught Little About Wartime Ethics 2Health News:1 size may not fit all 2Health News:Jack Welch to Headline the 8th Annual Lean Six Sigma Healthcare Summit 2Health News:Houston Employers Hear New Research That Supports the Case for Retail Clinics 2Health News:Houston Employers Hear New Research That Supports the Case for Retail Clinics 3Health News:Houston Employers Hear New Research That Supports the Case for Retail Clinics 4Health News:British Royal highlights anesthesia crisis in the developing world 2
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)FORT WORTH, Texas, Dec. 3 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today an agreement with the Health In
Breaking Medicine Technology:Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3West Announces Third Quarter 2009 Results 5943 1West Announces Third Quarter 2009 Results 5943 2West Announces Third Quarter 2009 Results 5943 3West Announces Third Quarter 2009 Results 5943 4West Announces Third Quarter 2009 Results 5943 5West Announces Third Quarter 2009 Results 5943 6West Announces Third Quarter 2009 Results 5943 7West Announces Third Quarter 2009 Results 5943 8West Announces Third Quarter 2009 Results 5943 9West Announces Third Quarter 2009 Results 5943 10West Announces Third Quarter 2009 Results 5943 11West Announces Third Quarter 2009 Results 5943 12West Announces Third Quarter 2009 Results 5943 13West Announces Third Quarter 2009 Results 5943 14West Announces Third Quarter 2009 Results 5943 15West Announces Third Quarter 2009 Results 5943 16West Announces Third Quarter 2009 Results 5943 17West Announces Third Quarter 2009 Results 5943 18West Announces Third Quarter 2009 Results 5943 19West Announces Third Quarter 2009 Results 5943 20West Announces Third Quarter 2009 Results 5943 21West Announces Third Quarter 2009 Results 5943 22Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 1Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 2Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 3Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 4Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 5Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 6Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 7Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 8Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 9Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 10Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 11Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 12Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 13Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 14Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 15Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 16Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 1Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 2Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 3
...48-week investigational regimen yielded nearly dou...ate on next-generation HCV protease inhibitor SCH ...HAGEN, Denmark, April 23 Schering-Plough Corporat...ts of the HCV SPRINT-1 study showed boceprevir, it...tor, in combination with peginterferon alfa-2b and...
... , , , FDA approval for testing in humans water..., , ROCKVILLE, Md., April 23 In a move that high...n in tackling international health challenges, the... from the PATH Malaria Vaccine Initiative (MVI), h... tests in adult volunteers -- of its unique malari...
Other Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 2Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 4
...G-9200 is a Windows 2000 PC based EEG with high pe... and software. EEG-9200 provides high quality perf...in the sleep lab or EEG lab. Quality EEG recording...CU. Neurofax has high performance, high sensitivit...
...act is the first magnetic stimulator to offer the ... stimulation. It is designed to provide the simple...tic routine (at the same time, it may also help re...ons without moving away from your patient). , ,...
Fidelity IAB Intra-Aortic Balloon Catheter
...series is a new top-line range of digital pacemake...rillation (AF). Because the T-series combines digi...reatment of AF is taken one step further. Thanks t...ored continuously and extensively. This gives phys...
Medicine Products: